Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer.

Julián Córdoba SánchezInés Monge-EscartínJavier GilCristina CarreraJoaquín Sáez-PeñataroLaura FerrerCaterina AversaBegoña MelladoJoel MasesMaria Jose RibalAntonio AlcarazAntoni Vilaseca

Published in: The Prostate (2024)

This study highlights the importance of MDT management of AEs associated with apalutamide to reduce treatment discontinuation.

Keyphrases

prostate cancer
smoking cessation